News about 'TB Drug Development'

Today on World TB Day, the International Scientific Exchange Foundation of China (ISEFC) , announced the signing of a Memorandum of Understanding with the Global Alliance for TB Drug Development (TB Alliance) to establish the Global Health R&D Center of China (GHRC). This innovative center will...

Summary: Dr. Eric Nuermberger is Associate Professor of Medicine in the Division of Infectious Diseases, Department of Medicine, at Johns Hopkins University School of Medicine. The WGND had the opportunity to talk with Dr. Nuermberger on a recent article entitled “PA-824 exhibits time-dependent...

Global Health Primer by Disease This week BIO Ventures for Global Health launched a new online tool called the “Global Health Primer” which aims to be a clearinghouse of information geared to the biotech industry to encourage investments in neglected disease product development. The Primer...

From Guardian (UK) (March 3, 2011) AstraZeneca has joined a consortium to fight tuberculosis around the world with French rival Sanofi-aventis, the University of Cambridge and other research organisations. The More Medicines for Tuberculosis (MM4TB) consortium intends to develop new drugs for...

2010 G-Finder Report The third annual G-Finder report, Neglected Disease Research and Development, was released on February 16, 2011. The report, compiled by the Policy Cures staff using information self-reported by granting and recipient institutions, provides the latest information on the funding...

Elkington PT, D’Armiento JM, Friedland JS. Tuberculosis immunopathology: the neglected role of extracellular matrix destruction. Sci Transl Med. 2011 Feb 23;3(71):71ps6. In today’s article, Elkington, et al., would like to change how researchers view and define immunopathology in tuberculosis. The...

In addition, other discussions in the policy realm toss around the idea that the government should get a return on the sale of drugs that were developed with federal funds in the face of high drug costs and medical care. This debate surrounding the public sectors role in downstream drug development...

Summary: Dr. Philip Bourne is a professor at the University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences and Editor in Chief of PL0S Computational Biology . The WGND had the opportunity to talk with Dr. Bourne on a recent article published in PLoS Computational...

Dr. Rajiv Shah, Administrator of the United States Agency for International Development (USAID), addressed the importance of investing in innovation and harnessing the power of new global health technologies to achieve widespread impact on those suffering from disease in the most impoverished...

[wpaudio url=”/blog/media/podcasts/Anne_Lenaerts_Interview_edited-norm.mp3″ text=”Anne Lenaerts Interview” dl=”0″] Summary: Dr. Anne Lenaerts is an associate professor at Colorado State University”s College of Veterinary Medicine and Biomedical Sciences in the Department of Microbiology, Immunology...

The Bill & Melinda Gates Foundation is now accepting letters of inquiry for the new grant program Biomarkers for the Diagnosis of Tuberculosis. This grant program is part of the Grand Challenges in Global Health initiative. With up to $12 million of funding, the program seeks to validate...

Chemical Structure of Pyrazinamide Ahmad Z, Fraig MM, Bisson GP, Nuermberger EL, Grosset JH, Karakousis PC. Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis. Antimicrob Agents Chemother. 2011 Jan 31. [Epub ahead of print] First discovered as...

Saunders NJ, Urmi HT, Thomson ML, Doig C, Laurenson IF, Blaxter ML. Stepwise mutation to multiple drug resistance in Mycobacterium tuberculosis in an otherwise stable genetic backgrounddoes not support models of high mutation in the host and emphasizes the need for maintained effective...

Ahmad Z, Peloquin CA, Singh RP, Derendorf H, Tyagi S, Ginsberg A, Grosset JH, Nuermberger EL. PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob Agents Chemother. 2011 Jan;55(1):239-45. Epub 2010 Oct 11.PMID: 20937781 [PubMed – in process] Researchers testing the...

The Wall Street Journal Health Blog reported that the FDA issued a draft guidance for the drug industry “designed to encourage companies to work in tandem to develop two or more new drugs to be used in combination to treat cancer and infectious diseases, among other illnesses.” This is exciting...